{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:21:03Z","timestamp":1758874863202},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this critical review, we explore the study design, strengths and limitations of the paper: \u201cTwo-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.\u201d The paper reports 24 month follow-up data of the landmark ROSETTA trial. This multi-centre, open-labelled parallel randomised trial allocated females 1:1 to receive Sacral Neuromodulation (SNM) or OnabotulinumtoxinA(BTX) 200 units (U). The primary outcome was change in mean daily urinary urgency incontinence episodes (UUIE) over 24 months. The study did not demonstrate a difference between treatments (-3.88 vs. -3.50 episodes per day), however women treated with BTX were more satisfied; but reported higher rates of UTI. The two treatments provide comparable third-line treatment options for patients with refractory urgency urinary incontinence.<\/jats:p>","DOI":"10.1186\/s12894-023-01385-5","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T17:02:08Z","timestamp":1705424528000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Seminal papers in urology: two-year outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a Randomized Trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Haidar Hadri bin","family":"Abd Wahab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"issue":"1","key":"1385_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.eururo.2013.08.031","volume":"65","author":"I Milsom","year":"2014","unstructured":"Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen C-I, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65(1):79\u201395.","journal-title":"Eur Urol"},{"issue":"1","key":"1385_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2022.01.045","volume":"82","author":"AK Nambiar","year":"2022","unstructured":"Nambiar AK, Arlandis S, B\u00f8 K, Cobussen-Boekhorst H, Costantini E, de Heide M, et al. European association of urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. Eur Urol. 2022;82(1):49\u201359.","journal-title":"Eur Urol"},{"issue":"3","key":"1385_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","volume":"202","author":"DJ Lightner","year":"2019","unstructured":"Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019. J Urol. 2019;202(3):558\u201363.","journal-title":"J Urol"},{"issue":"1","key":"1385_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12916-017-0828-2","volume":"15","author":"R Riemsma","year":"2017","unstructured":"Riemsma R, Hagen S, Kirschner-Hermanns R, Norton C, Wijk H, Andersson K-E, et al. Can incontinence be cured? A systematic review of cure rates. BMC Med. 2017;15(1):63.","journal-title":"BMC Med"},{"issue":"13","key":"1385_CR5","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1001\/jama.2016.14617","volume":"316","author":"CL Amundsen","year":"2016","unstructured":"Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316(13):1366\u201374.","journal-title":"JAMA"},{"issue":"1","key":"1385_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.eururo.2018.02.011","volume":"74","author":"CL Amundsen","year":"2018","unstructured":"Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, et al. Two-year outcomes of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial. Eur Urol. 2018;74(1):66\u201373. https:\/\/doi.org\/10.1016\/j.eururo.2018.02.011. Epub 2018 Feb 24. PMID: 29482936; PMCID: PMC6004242.","journal-title":"Eur Urol"},{"issue":"2","key":"1385_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.cct.2014.01.009","volume":"37","author":"CL Amundsen","year":"2014","unstructured":"Amundsen CL, Richter HE, Menefee S, Vasavada S, Rahn DD, Kenton K, et al. The refractory overactive bladder: sacral neuromodulation vs. botulinum toxin assessment: ROSETTA trial. Contemp Clin Trials. 2014;37(2):272\u201383.","journal-title":"Contemp Clin Trials"},{"key":"1385_CR8","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JA Sterne","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366;4898.","journal-title":"BMJ"},{"issue":"5","key":"1385_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1097\/JU.0000000000000656","volume":"203","author":"HS Harvie","year":"2020","unstructured":"Harvie HS, Amundsen CL, Neuwahl SJ, Honeycutt AA, Lukacz ES, Sung VW, et al. Cost-effectiveness of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: results of the ROSETTA randomized trial. J Urol. 2020;203(5):969\u201377.","journal-title":"J Urol"},{"key":"1385_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00192-020-04427-w","volume":"32","author":"Q He","year":"2021","unstructured":"He Q, Li B, Zhang C, Zhang J, Luo D, Wang K. Treatment for refractory overactive bladder: a systematic review and meta-analysis of sacral neuromodulation and onabotulinumtoxinA. Int Urogynecol J. 2021;32:477\u201384.","journal-title":"Int Urogynecol J"},{"issue":"1","key":"1385_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.juro.2011.09.052","volume":"187","author":"HW Chen","year":"2012","unstructured":"Chen HW, Bercik RS, Werner EF, Thung SF. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release Tolterodine for overactive bladder. J Urol. 2012;187(1):178\u201384.","journal-title":"J Urol"},{"issue":"1","key":"1385_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.juro.2012.08.085","volume":"189","author":"M Martinson","year":"2013","unstructured":"Martinson M, MacDiarmid S, Black E. Cost of Neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. J Urol. 2013;189(1):210\u20136.","journal-title":"J Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-023-01385-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-023-01385-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-023-01385-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T17:03:47Z","timestamp":1705424627000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-023-01385-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1385"],"URL":"https:\/\/doi.org\/10.1186\/s12894-023-01385-5","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"10 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}